Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Activated prothrombin complex concentrates: approaches to their preparation.

C V Prowse

    Thrombosis Research
    |February 1, 1982
    PubMed
    Summary

    Locally produced activated prothrombin complex concentrates were compared to commercial versions. One preparation, Bridge Anticoagulant Neutralising Activity, showed promise for treating hemophilia patients with inhibitors.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Commercially available blood storage containers.

    Vox sanguinis·2013
    Same author

    Component pathogen inactivation: a critical review.

    Vox sanguinis·2012
    Same author

    Characteristics of prion-filtered red cells suspended in pathogen-inactivated plasma (MB treated or solvent-detergent treated) for neonatal exchange transfusion.

    Vox sanguinis·2010
    Same author

    Stored red-blood-cells inhibit platelet function under physiologic flow.

    Vox sanguinis·2010
    Same author

    Tissue plasminogen activator in human plasma measured by radioimmunoassay.

    Thrombosis research·2010
    Same author

    Platelet storage in Fresenius/NPBI polyolefin and BTHC-PVC bags: a direct comparison.

    Transfusion medicine (Oxford, England)·2008

    Area of Science:

    • Coagulation science
    • Hematology
    • Pharmacology

    Background:

    • Hemophilia A patients can develop inhibitors to Factor VIII, complicating treatment.
    • Prothrombin complex concentrates (PCCs) are used to bypass inhibitors, but their efficacy varies.
    • Activated PCCs (aPCCs) offer an alternative treatment strategy.

    Purpose of the Study:

    • To compare the inhibitor bypassing activity of locally produced activated PCCs with commercial aPCCs.
    • To investigate the composition and activity of a novel preparation, Bridge Anticoagulant Neutralising Activity (BANA).

    Main Methods:

    • Activation of locally produced PCCs using various methods.
    • Comparison of inhibitor bypassing activity using a clotting time assay with hemophilic plasma containing Factor VIII inhibitors.
    • Analytical chromatography to determine the composition of activated concentrates.

    Main Results:

    • Locally produced and commercial activated PCCs exhibited inhibitor bypassing activity.
    • Analytical chromatography indicated that activity was primarily due to classical activated coagulation factors.
    • The BANA preparation demonstrated significant inhibitor bypassing potential.

    Conclusions:

    • The inhibitor bypassing activity of activated PCCs is largely attributable to known activated coagulation factors.
    • The BANA preparation warrants further in vivo investigation for potential use in inhibitor patients.

    Related Experiment Videos